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Positron emission tomography (PET) integrated with computed tomography (PET/CT) has been reported to be
useful for screening myelomatous lesions at diagnosis in patients with multiple myeloma (MM) and for
monitoring response to autologous stem cell transplantation (auto-SCT). The aim of the study was to evaluate
the prognostic signiﬁcance of PET/CT in MM patients who received allogeneic stem cell transplantation (allo-
SCT). Patients who underwent upfront auto-SCT followed by allo-SCT, either as consolidation or salvage
treatment, were studied with PET/CT before and/or within 6 months after allo-SCT. The number, the
maximum standard uptake value (SUV), and the location (medullary or extramedullary) of focal lesions (FLs)
were recorded and investigated as predictors of progression-free survival (PFS) and overall survival (OS) by
univariate and multivariate analyses. Fifty-four patients had a PET/CT scan before allo-SCT. Of these, 22
patients (41%) had a negative PET/CT scan, 11 patients (20%) showed 1 to 3 FLs, and 21 patients (39%) had
either a diffuse bone marrow involvement or more than 3 FLs. SUV was >4.2 in 21 patients (39%) and
extramedullary disease (EMD) was present in 6 patients (11%). Multivariate analysis of prognostic factors
before allo-SCT showed that persistence of EMD at transplantation was an independent predictor of poor PFS,
whereas OS was negatively inﬂuenced by unrelated donor and SUV > 4.2. Fifty-nine patients had a PET/CT
scan within 6 months after allo-SCT. Multivariate analysis of post-treatment variables showed that persis-
tence of EMD and failure to obtain complete response or very good partial response after allo-SCT were
strongly associated with shorter PFS and OS. Of the 46 patients with evaluable PET/CT scans both before and 6
months after allo-SCT, the 23 patients who maintained or reached a PET complete remission showed a
signiﬁcantly prolonged PFS and OS compared with the 23 patients with persistence of any PET positivity (2-
year PFS: 51% versus 25%, P ¼ .03; 2-year OS: 81% versus 47%, P ¼ .001). This study indicates that PET/CT
imaging before and after allo-SCT is signiﬁcantly associated with the outcome, suggesting the utility of this
technique for MM staging before allo-SCT and for response monitoring after the transplantation.
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The majority of patients with multiple myeloma (MM)
present bone disease at diagnosis or develop it during the
course of the disease. Traditionally, bone disease is detected
by skeletal X-ray survey and is characterized by sharply
deﬁned lytic lesions, vertebral collapses, and pathological
fractures, which could persist unchanged for a long time
after therapy, despite effective treatment. In recent years,
there has been an increasing interest in improving imaging
techniques in MM. Features of an optimal imaging technique
include high sensitivity for detecting lytic bone lesions and
inﬁltrative focal lesions (FLs) in the bone marrow (BM),
reliability in detecting extramedullary disease (EMD), and
ability to assess response to treatment [1]. Low-dose
computed tomography, magnetic resonance (MR), and
positron emission tomography (PET) integrated with
computed tomography (PET/CT) using the positron emitting
radionucleotide 18F-ﬂuorodeoxyglucose (FDG) have some of
the above-mentioned characteristics. In particular, PET/CT
can provide anatomic and functional information in MM. In
fact, PET/CT is useful for detecting the extent of bone disease
in patients with newly diagnosed MM because it is superior
to skeletal X-ray survey in terms of its ability to reveal
medullary and extramedullary bone lesions, leading in some
cases to a change in disease stage and treatment [2-6].
Therefore, the updated criteria for the diagnosis of MM have
recently established that PET-CT is 1 of the new tools to
precociously identify bone disease [7]. Moreover, PET/CT at
diagnosis is a reliable technique for predicting long-term
outcome in MM patients. In fact, 2 independent prospec-
tive studies showed that PET/CT at diagnosis provides prog-
nostic information on both progression-free survival (PFS)
and overall survival (OS) in MM patients treated with in-
duction therapy with novel agents and autologous stem cell
transplantation (auto-SCT) [5,6]. The Little Rock study
showed a close correlation between the number of FLs found
by MR (>7 lesions) and PET/CT (>3 lesions) and other bio-
logical prognostic factors and gene expression proﬁling re-
sults [5]. The Bologna group demonstrated that patients with
newly diagnosed MMwho presented with more than 3 FLs, a
high standardized uptake value (SUV), and extramedullary
disease (EMD) on diagnostic PET/CT had a poor PFS [6]. PET-
CT has been an useful tool not only for staging at diagnosis,
but also for monitoring the response after treatment, as
demonstrated by some studies mainly conducted on patients
undergoing auto-SCT [8,9].
The purpose of this study is to analyze the prognostic
signiﬁcance of PET/CT performed before and after trans-
plantation in a series of patients with MM who received
allogeneic stem cell transplantation (allo-SCT).
METHODS
Patients
Data on 67 MM patients were retrospectively collected in 4 centers
under a protocol approved by the institutions participating in this study.
This study was structured as follows: (1) a synopsis of the study was sent to
the centers; after their agreement to join the study, they received a letter
explaining how to collect the data required on a speciﬁc patient form; (2)
each center designated an investigator in charge of the study; (3) the centers
reviewed all MM patients who underwent allo-SCT between 2004 and 2011
and included those patients who were studied with PET/CT before the
procedure and/or during the follow-up after allo-SCT (with at least an
evaluable scan within 6 months after allo-SCT); and (4) the patient forms
coming back from the centers were reviewed by a statistician and a senior
hematologist and, if necessary, speciﬁc queries were sent back to the
centers.
Disease response was evaluated through clinical examination, blood
chemistry, and BM biopsy. Besides PET/CT, bone disease was studied withstandard imaging techniques (whole skeleton X-ray survey and spine MR,
according to the policy of each center). Karyotype was analyzed at diagnosis
by the ﬂuorescence in situ hybridization (FISH) technique, if available, to
assess the following baseline abnormalities: t(4;14), deletion 17p13, and
deletion 13q14. Response was evaluated according to the international
Uniform Response Criteria for MM [10].
Imaging Studies
Whole body (including skull, superior limbs, and femurs) PET/CT was
carried out using standard procedures, as previously described [11]. All of
the PET/CT scan were evaluated by a team of nuclear medicine physicians
with extensive experience in MM ﬁeld. The interpretation criteria for the
baseline PET scans and the PET response adopted in this study were used in
2 previous papers of the groups of Bologna and Udine [6,9] and were shared
by the physicians of nuclear medicine of the 4 centers. In case of doubt, the
case was reviewed by the Bologna team. Criteria to deﬁne PET/CT positivity
included the following: (1) presence of focal areas of detectable increased
tracer uptake within bones (excluding articular processes) with or without
any underlying lesion identiﬁed by CT; or (2) maximum SUV (SUVmax) 2.5
within bone lytic CT areas exceeding 1 cm in size; or (3) SUVmax  1.5
within osteolytic CT areas ranging between .5 and 1 cm in size.
The number, size, and location of hypermetabolic FLs were recorded. BM
uptake on PET/CT was described as negative, diffuse, or focal according to
the degree of FDG uptake. BMwas considered diffusely involved if the tracer
uptake was diffusely increased, with an SUVmax equal to or greater than the
uptake in the spleen. In this case, the SUVmax was measured in the hottest
area within the BM. The degree of FDG uptake was represented by the
SUVmax in the hottest lesion. EMD, deﬁned by soft tissue or visceral FDG
uptake that can be adjacent to a bone lesion (bone-related EMD) or not
linked to the bone (soft-tissueerelated EMD) [12], was described by loca-
tion, size, number, and SUV.
PET/CT scans were performed within 30 days before allo-SCT and/or
during the follow-up after allo-SCT (between the third and the sixth months
after allo-SCT and then every 12 months, according to the decision of the
attending physician).
In patients inwhom 1 PET/CT scan before allo-SCT and 1 or more PET/CT
scans after allo-SCT were evaluable, PET/CT complete remission (PET-CR) was
deﬁned as disappearance of every area of increased tracer uptake found at
baseline. PET/CT partial remission (PET-PR) was deﬁned as a decrease in the
number of sites of FDG uptake and/or a decrease of at least 20% in the
SUVmax of the lesions. PET relapse or progressionwas deﬁned as an increase
> 50% of the residual FLs or appearance of new FLs or EMD by PET/CT.
Statistical Analysis
Data were collected in an XLS database and imported into Stata/SE 9.0
for Windows for statistical analysis. The close-out date for analysis was
October 2013.
Nonrelapse mortality (NRM) was deﬁned as death due to all causes not
related to myeloma. OS was deﬁned as the time (months) from allo-SCT to
either death or last observation. PFSwas deﬁned as the time from allo-SCT to
relapse, progression, death, or last observation. OS and PFS were described
using the Kaplan-Meier approach. The cumulative incidence method was
used to estimate relapse and NRM, accounting for the presence of competing
risk. NRM and overall mortality were considered as events. The time to
event was measured as months from transplantation. Graphs of time to
event were based on the Kaplan-Meier method. OS and PFS were analyzed
using Cox proportional hazard models, after the proportional hazards
assumption had been veriﬁed.
Associations with clinical characteristics were compared by the chi-
square method for categorical data and the t-test was used to compare
continuous variables. In univariate analysis, variables considered as possible
prognostic factors were age at transplantation (years), stage according to
Durie and Salmon (IþII versus III), time between diagnosis and allo-SCT
(months), donor (HLA-identical sibling versus unrelated), timing of allo-
SCT (at diagnosis versus at relapse), response before allo-SCT (CRþvery
good partial response [VGPR] versusPR), number of FLs at PET scan before
transplantation (0 versus 1), SUV at PET scan before transplantation (<4.2
versus 4.2), EMD sites at PET scan before transplantation (0 versus 1),
response 6 months after allo-SCT (CRþVGPR versus  PR), number of FLs at
PET scan 6 months after allo-SCT (0 versus 1), SUV at PET scan 6 months
after allo-SCT (<4.2 versus 4.2), and EMD sites at PET scan 6 months after
allo-SCT (0 versus 1). International Staging System score (ISS) and karyo-
type were not considered as possible variables of the univariate analysis
because of the high number of missing data (58% and 52%, respectively). The
cutoffs for FLs and SUV were identiﬁed after applying the sequential log-
rank test and selecting the most powerful values for discriminating the
outcome. Multivariate stepwise analysis included all variables signiﬁcant at
P  .10 in the univariate analysis and was conducted separately for
Table 1
Clinical Characteristics of the Patients and Transplantations
Characteristic All
Patients
Patients with an
Evaluable PET/CT
before Allo-SCT
Patients with
an Evaluable
PET/CT
after Allo-SCT
No. of patients 67 54 59
Age at allo-SCT,
median (range), yr
55 (32-69) 50 (32-65) 50 (32-65)
Stage according
Durie & Salmon
I 8 (12%) 8 (15%) 6 (10%)
II 2 (3%) 2 (4%) 2 (3%)
III A 51 (76%) 39 (72%) 46 (78%)
III B 6 (9%) 5 (9%) 5 (9%)
Stage according ISS
1 8 (34%) 7 (29%) 6 (26%)
2 6 (26%) 5 (21%) 5 (22%)
3 14 (50%) 12 (50%) 12 (52%)
Not evaluated 39 30 36
Karyotype
Standard risk 20 (63%) 18 (64%) 16 (59%)
High-risk: del13,
del17, t(4;14)
12 (37%) 10 (36%) 11 (41%)
Not evaluated 35 26 32
Tandem auto-SCT þ
RIC allo-SCT
27 (40%) 17 (31%) 25 (42%)
RIC allo-SCT at relapse 40 (67%) 37 (69%) 34 (58%)
Donor
HLA-matched sibling 29 (43%) 18 (23%) 26 (44%)
Unrelated 38 (57%) 36 (77%) 33 (56%)
Disease status
before allo-SCT
CR 13 (19%) 13 (24%) 12 (21%)
VGPR 17 (26%) 9 (18%) 14 (24%)
PR 17 (26%) 13 (24%) 14 (24%)
SD or progression 19 (29%) 18 (34%) 18 (31%)
Not evaluated 1 1 1
RIC indicates reduced-intensity conditioning; SD, stable disease.
Data presented are n (%) unless otherwise indicated.
Table 2
Characteristics of PET/CT Scan
Time of Evaluation Before Allo-SCT After Allo-SCT
No. of patients 54 59
No focal lesions 22 (41%) 29 (47%)
1-3 FL (%) 11 (20%) 8 (15%)
> 3 FL or diffuse (%) 21 (39%) 22 (38%)
SUV (%)
Low (4.2) 30 (61%) 43 (85%)
High (>4.2) 21 (39%) 15 (15%)
Not evaluated 3 1
Extramedullary disease 6 (11%) 8
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stepwise model required that the variable be signiﬁcant at P  .05 in
multivariate analysis.RESULTS
Patients Clinical Features and Clinical Outcome
A total of 67 patients with a median age of 55 years
(range, 32 to 69) at the time of allo-SCT were analyzed. The
main characteristics of the patients and of the treatment are
summarized in Table 1. Thirteen patients (19%) showed high-
risk clinical features at onset of MM: 6 patients presented
with renal impairment (creatinine > 2 mg/dL), 3 had hy-
percalcemia, 3 had meningeal or cerebral plasma cell local-
izations, and 1 had plasma cell leukemia. Because MM was
diagnosed before 2004 in 64% of the patients, ISS staging
data at diagnosis were evaluable only in 28 patients and 14 of
them (50%) had ISS stage II and III. Overall, 32 patients (48%)
were screened for cytogenetics abnormalities by FISH anal-
ysis performed on BM CD138þ plasma cells, and it indicated
that translocation(4;14) and/or deletion 17p13 and/or dele-
tion 13q14, occurred in 12 patients (37%).
All patients received upfront auto-SCT at a median time of
9 months (range, 3 to 54) after MM diagnosis. Auto-SCT was
followed by allo-SCT within 3 months in 27 cases (auto-allo
approach), whereas in the other 40 cases allo-SCT was per-
formed after failure of previous auto-SCT. Induction therapy
was based on vincristine, adriamicin, and dexamethasone in
10 patients or included immunomodulating agents and/or
bortezomib in the other 14 patients treated with the auto/allo approach. Among the 40 patients who underwent allo-
SCT at relapse, 26 patients (65%) had received 1 line of
salvage therapy and the other 14 patients (35%) were treated
with 2 lines of antimyeloma therapy, including immuno-
modulating agents and/or bortezomib in 96% of cases.
Median time between diagnosis and allo-SCT was 36 months
(range, 8 to 128).
Preparative regimens before allo-SCT were reduced-
intensity conditioning or nonmyeloablative regimens.
These regimens consisted of ﬂudarabine plus melphalan 140
mg/m2 in 36 patients (54%), ﬂudarabine plus 2 Gy total body
irradiation in 23 patients (34%), and miscellaneous combi-
nations in the remaining 8 patients.
Twenty-nine patients (43%) underwent transplantation
from HLA-identical sibling donors and 38 (57%) from unre-
lated donors.
At a median follow-up of 6 months (range, 1 to 122) after
allo-SCT for the whole population and of 41 months (range, 5
to 122) for the surviving patients, 34 patients (51%) experi-
enced relapse and 35 patients (52%) had died. Two-year cu-
mulative incidence of NRM was 23% and 2-year estimates of
PFS and OS after allo-SCT were 44% and 67%, respectively.
Patients treated with the auto-allo approach showed 2-year
estimates of PFS and OS after transplantation of 56% and
80%, respectively, compared with 36% (P¼ .027) and 58% (P¼
.051) for the patients who received allo-SCT after failure of
previous auto-SCT.PET/CT Imaging before Allo-SCT and Its Prognostic
Signiﬁcance
Fifty-four patients had an evaluable PET/CT scan before
allo-SCT (Table 2). Of these, 22 patients (41%) had a negative
PET/CT scan, 11 (20%) showed 1 to 3 FLs, and 21 (39%) had
either diffuse BM involvement or more than 3 FLs. In 21
patients (39%), baseline FDG uptake was severe (deﬁned as
SUV > 4.2). EMD was present in 6 patients (11%) in the
following sites: paranasal sinuses (n ¼ 1), pleura (n ¼ 1),
central nervous system (n ¼ 1), soft tissue of the pelvis (n ¼
2), and liver (n ¼ 1).
Among the 53 evaluable patients, according the Uniform
Response Criteria, depth of response correlated with PET
results before allo-SCT. In fact, 8 of 13 (61%) patients in CR
were PET negative compared with 13 of 40 (32%) patients in
VGPR or less (P¼ .04). However, 3 patients in CR showed 1 to
3 FLs at PET scan and the other 2 patients in CR presented
more than 3 FLs.
On univariate analysis, transplantation in relapse,
achievement of less than CR or VGPR, persistence of at least 1
FL, SUV > 4.2, and EMD before allo-SCT adversely affected
PFS and OS after allo-SCT. Moreover, allo-SCT from an unre-
lated donor was signiﬁcantly associated with shorter PFS and
Figure 1. Comparison of PFS (A) and OS (B) from the time of allogeneic transplantation between patients with no focal lesions (FLs) and patients with 1 FLs at
pretransplantation PET/CT (P ¼ .033 and P ¼ .075, respectively). Continuous line ____: no FL; dotted line ———: 1 FLs.
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sibling donor. In more detail, patients with 1 FL had 2-
year estimates of PFS and OS of 21% and 49%, respectively,
compared with 56% (P ¼ .033) and 72% (P ¼ .075) for those
without FLs at PET/CT scan before allo-SCT (Figure 1A,B).
Similarly, 2-year estimates of PFS and OS from the time of
allo-SCT for patients with baseline SUV values >4.2 were
signiﬁcantly shorter that those observed for patients with
SUV< 4.2 (PFS: 16% versus 51%, P¼ .031; OS: 42% versus 72%,
P ¼ .013) (Figure 2A,B). Moreover, patients with EMD had 2-
year PFS and OS estimates of 12% and 33%, respectively,
compared with 50% (P ¼ .010) and 62% (P ¼ .016) for those
without EMD.
In a Cox regression analysis of prognostic factors before
allo-SCT, persistence of EMD at transplantation was an
independent predictor of poor PFS after allo-SCT. OS was
negatively inﬂuenced by unrelated donor and SUV > 4.2
(Table 3).PET/CT Imaging after Allo-SCT and Its Prognostic
Relevance
Fifty-nine patients had a PET/CT scan within 6 months
after allo-SCT. Of these, 29 patients (47%) had a negative PET/
CT, whereas 8 (15%) showed between 1 and 3 FLs and 22
(38%) had more than 3 FLs.Figure 2. Comparison of PFS (A) and OS (B) from the time of allogeneic transplantatio
SUV > 4.2 at pretransplantation PET/CT (P ¼ .031 and P ¼ .013, respectively). ContinuOn univariate analysis, achievement of less than CR and
VGPR and persistence of EMD after allo-SCT adversely
affected PFS and OS, whereas presence of at least 1 FL was
signiﬁcantly associated with shorter OS after allo-SCT. Two-
year estimates of PFS and OS of patients with positive EMD
were signiﬁcantly lower than those of patients without EMD
(PFS: 12% versus 52%, P¼ .000; OS: 25% versus 82%, P¼ .001).
Multivariate analysis of post-treatment variables showed
that persistence of EMD and failure to obtain CR or VGPR
after allo-SCT were strongly associated with shorter PFS and
OS from the time of allo-SCT (Table 4).Response Assessment after Allo-SCT by PET/CT Scans
Forty-six patients had a PET/CT scan before allo-SCT and
at 6 months after the procedure. Before allo-SCT, 14 of the 46
patients (30%) had a negative PET/CT, whereas the other 32
(70%) had at least 1 positive FL. The 23 patients who main-
tained or reached a PET/CR at the sixth month after allo-SCT
showed a signiﬁcantly prolonged PFS and OS compared with
the other 23 cases with persistence of any PET positivity (2-
year PFS: 51% versus 25%, P ¼ .03; 2-year OS: 81% versus 47%,
P ¼ .001) (Figure 3A,B).
A total of 69 PET/CT scans were performed during the
follow-up after allo-SCT in 17 patients, with a median of 4
yearly examinations. Five patients maintained or reachedn between patients with standard uptake value (SUV)  4.2 and patients with
ous line ____: SUV  4.2; dotted line ———: >4.2.
Table 3
Multivariate Analysis of Pretransplantation Factors Affecting PFS and OS
Factor PFS OS
HR 95% CI P Value HR 95% CI P Value
Donor
Sibling matched / / / 1
Unrelated / / / 2.71 1.00-7.32 .049
SUV at T0 PET 1
<4.2 / / / 3.00 1.29-6.99 .010
4.2 / / /
Extramedullary sites at T0 PET
0 1 / / /
 1 3.89 1.57-9.64 .003 / / /
HR indicates hazard ratio; CI, conﬁdence interval; T0 PET, PET before allo-
geneic transplantation.
F. Patriarca et al. / Biol Blood Marrow Transplant 21 (2015) 1068e10731072PET-CR after allo-SCT: 3 died because of NRM and 2 are in
continuous CR according to the Uniform Response Criteria
and imaging after 75 and 105 months. Two patients showed
worsened PET/CT scans after allo-SCTand died of progression
at 10 and 30 months after transplantation. The other 10
patients showed 1 or more improved PET/CT scans after allo-
SCT. Of these, 4 patients showed a transient PET-PR followed
by clinical relapse and death due to progression, 1 patient
died of NRM, and the other 5 patients are long-term survi-
vors and present evidence of PET response to immuno-
manipulation (cyclosporine withdrawn or administration of
donor lymphocyte infusions) and antimyeloma therapy.DISCUSSION
Several studies have investigated the role of FDG-PET or
PET/CT in monitoring the response to treatment in patients
with MM, suggesting that persistence of metabolically active
lesions after conventional treatment or auto-SCT is an un-
favorable prognostic factor [13-19]. The most remarkable
results have come from the prospective studies of the Little
Rock and Bologna groups in newly diagnosed MM patients
treated with bortezomib-based induction therapy and auto-
SCT. In these studies, incomplete FDG suppression after auto-
SCT was strongly associated with a worse PFS and OS, both
for the 239 patients treated with “total therapy 3” program
[20] and for the 192 patients treated with novel agentebased
induction and auto-SCT [9,21]. Moreover, the Little Rock
group recently reported the prognostic value of early PET/CT
performed at day 7 of the induction treatment: patients
presenting more than 3 FLs had a 3-year OS and PFS of 63%
and 56%, respectively, compared with 78% and 82% for pa-
tients with 1-3 FLs [8].
Our study is the ﬁrst investigation focused on the prog-
nostic relevance of PET/CT results in patients undergoing
allo-SCT and the ﬁrst PET scan was performed before allo-
SCT. There is strong evidence that the quality of clinical andTable 4
Multivariate Analysis for Post-transplantation Factors Affecting PFS and OS
Factor PFS OS
HR 95% CI P Value HR 95% CI P Value
Response to transplantation
CR þ VGPR 1 / 1
PR 2.96 1.37-6.37 .006 3.65 1.34-9.93 .011
Extramedullary sites at T1 PET
0 1 1
1 7.29 2.79-19.04 .000 7.84 2.44-25.17 .001
T1 PET indicates PET 6 months after allogeneic transplantation.biochemical response before transplantation correlates with
the subsequent outcome after myeloablative transplantation
as well as after reduced-intensity conditioning regimens [22-
24]. Moreover, the degree of HLA matching signiﬁcantly in-
ﬂuences NRM [25]. We conﬁrmed that failure to achieve CR
and VGPR before allo-SCT was signiﬁcantly associated with
an unfavorable outcome, but we also showed that, similar to
what has already been described in patients treated
with conventional and high-dose therapy and auto-
transplantation, PET/CT added prognostic information, since
the entity of PET/CT involvement as reﬂected by persistence
of at least 1 FL, high intensity of tumor metabolism (SUV
value > 4.2), and presence of EMD before allo-SCT were
predictors of shorter PFS and OS. In multivariate analysis,
only PET/CT data (persistence of EMD and higher SUV value
before allo-SCT) and transplantation from unrelated donors
were found to be independent prognostic factors for a worse
outcome, suggesting that PET is a useful tool to deﬁne the
extent of disease before allo-SCT in order to choose the
proper intensity of the conditioning regimen and GVHD
prophylaxis.
It is well known that PET/CT is the best imaging technique
for detecting EMD because of its wider, whole-body ﬁeld of
view, and that the presence of EMD at diagnosis or EMD
development during the disease course negatively affect MM
prognosis, which is worse in patients with bone-unrelated
EMD compared with those with bone-related EMD [12].
Because of the limited number of patients with EMD, we
considered patients with bone-related and those with bone-
unrelated EMD together, conﬁrming the results reported in
the study of Zamagni et al. [5], which included only the cases
with bone-unrelated EMD. In our study, persistence of EMD
before allo-SCT and 6 months after transplantation was a
strong and independent predictor of unfavorable outcome,
indicating that EMD is an aggressive MM entity that can be
resistant to new drugs and escape immunological control
after allo-SCT. The negative prognostic impact of EMD
persistence at PET/CT could suggest that a speciﬁc treatment
should be given to patients with residual EMD, eg, adding
local radiotherapy in involved ﬁelds identiﬁed by PET scans.
Moreover, during the follow-up after allo-SCT, we
observed that patients who maintained or achieved PET
negativity (PET/CR) 6 months after allo-SCT had a signiﬁcant
PFS and OS advantage. This information could suggest the
addition of consolidation treatment with new drugs, with-
drawal of GVHD prophylaxis, or administration of donor
lymphocyte infusions in patients with persistence of FDG
uptake at PET/CT performed 6 months after allo-SCT.
Furthermore, we described the management of a subgroup
of 17 patients followed with serial yearly PET scans, in whom
modulation of immune-suppression and eventual salvage
treatment were driven on the basis of clinical response in-
tegrated with PET imaging.
We acknowledge that our study has some limitations.
First, its retrospective nature could have induced heteroge-
neity in the study population (eg, timing of the allo-SCT) and
missing information in the data collection (eg, FISH karyo-
type and ISS staging at diagnosis), which was minimized by
sharing treatment policy and study protocol among the
participating institutions. Second, PET/CT scan before and
after allo-SCT were available only for some of the patients
and a serial assessment of the response during the follow-up
after allo-SCT was available in a minority of patients. Finally,
there is still a need to standardize the criteria for PET/CT
imaging deﬁnitions and interpretation in MM.
Figure 3. Comparison of PFS (A) and OS (B) from the time of allogeneic transplantation between patients who maintained or reached PET CR 6 months after allo-SCT
in comparison with patients with PET PR, stable disease, or PET progression (P ¼ .03 and P ¼ .001, respectively). Continuous line ____: PET CR; dotted line ———: PET
PR, stable disease, or PET progression.
F. Patriarca et al. / Biol Blood Marrow Transplant 21 (2015) 1068e1073 1073In conclusion, our study indicates that PET/CT imaging
before and 6 months after allo-SCT is a predictor for long-
term outcome in allografted patients, suggesting that PET/
CT is a reliable technique for MM staging before allo-SCT and
response monitoring during follow-up. PET/CT results could
contribute to individualization of conditioning regimens and
immune-manipulation after transplantation.
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